ACN vs MSFT

Accenture (ACN) exhibits mixed fundamental health, with a Piotroski F-Score of 4/9 indicating a borderline stable financial position, and no Altman Z-Score available to assess distress risk. The stock trades at a premium to its Graham Number ($116.86) and intrinsic value estimate ($84.7), suggesting valuation is driven by growth expectations rather than conservative safety. Despite strong profitability metrics—ROE of 25.02% and gross margin of 31.97%—earnings growth has turned negative (-1.60% YoY), and recent price performance reflects significant underperformance over 1Y (-39.2%) and 5Y (-20.8%). Analysts remain optimistic with a buy recommendation and a target price of $268.51, but insider activity is neutral, and technical trends are bearish.

Microsoft exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust financial stability. While the stock is currently experiencing a severe technical downtrend (0/100) and significant 6-month price depreciation (-28.6%), the current price of $374.33 sits well below the growth-based intrinsic value of $471.41 and the analyst target of $587.31. Exceptional earnings growth (59.8% YoY) and high operating margins (47.09%) suggest that the current price correction presents a value opportunity despite bearish insider sentiment.